Antares Pharma, Inc. (NASDAQ:ATRS) - Stock analysts at Zacks Investment Research upped their FY2018 earnings per share (EPS) estimates for Antares Pharma in a report released on Wednesday. Zacks Investment Research analyst J. Vandermosten now expects that the specialty pharmaceutical company will post earnings of $0.04 per share for the year, up from their prior forecast of $0.03. Zacks Investment Research also issued estimates for Antares Pharma’s FY2019 earnings at $0.39 EPS.
Antares Pharma (NASDAQ:ATRS) last issued its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.01. Antares Pharma had a negative return on equity of 41.37% and a negative net margin of 34.27%. The business had revenue of $13.42 million during the quarter, compared to analyst estimates of $12.99 million.
A number of other research firms have also weighed in on ATRS. Vetr lowered shares of Antares Pharma from a “buy” rating to a “hold” rating and set a $3.42 price target on the stock. in a research report on Wednesday, July 12th. Piper Jaffray Companies set a $4.00 price target on shares of Antares Pharma and gave the company a “buy” rating in a research report on Wednesday, July 26th. HC Wainwright set a $5.00 price target on shares of Antares Pharma and gave the company a “buy” rating in a research report on Wednesday. Chardan Capital assumed coverage on shares of Antares Pharma in a research report on Friday, June 23rd. They set a “buy” rating and a $5.00 price target on the stock. Finally, Raymond James Financial, Inc. assumed coverage on shares of Antares Pharma in a research report on Thursday, April 20th. They set a “strong-buy” rating and a $4.30 price target on the stock. One equities research analyst has rated the stock with a hold rating, three have assigned a buy rating and two have assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $3.83.
Shares of Antares Pharma (NASDAQ ATRS) traded up 2.09% during trading on Thursday, reaching $2.93. The company had a trading volume of 1,188,761 shares. The company’s market cap is $458.27 million. The firm has a 50-day moving average of $3.14 and a 200-day moving average of $2.77. Antares Pharma has a 12-month low of $1.03 and a 12-month high of $3.37.
A number of hedge funds have recently made changes to their positions in the company. Citadel Advisors LLC raised its stake in shares of Antares Pharma by 350.5% in the first quarter. Citadel Advisors LLC now owns 83,882 shares of the specialty pharmaceutical company’s stock valued at $238,000 after buying an additional 65,262 shares in the last quarter. Morgan Stanley raised its stake in shares of Antares Pharma by 153.3% in the first quarter. Morgan Stanley now owns 996,113 shares of the specialty pharmaceutical company’s stock valued at $2,829,000 after buying an additional 602,834 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Antares Pharma by 4.8% in the first quarter. Geode Capital Management LLC now owns 958,234 shares of the specialty pharmaceutical company’s stock valued at $2,721,000 after buying an additional 43,629 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Antares Pharma by 4.3% in the first quarter. Vanguard Group Inc. now owns 5,619,088 shares of the specialty pharmaceutical company’s stock valued at $15,958,000 after buying an additional 232,349 shares in the last quarter. Finally, Segantii Capital Management Ltd raised its stake in shares of Antares Pharma by 552.4% in the first quarter. Segantii Capital Management Ltd now owns 189,200 shares of the specialty pharmaceutical company’s stock valued at $537,000 after buying an additional 160,200 shares in the last quarter. 31.70% of the stock is currently owned by institutional investors and hedge funds.
In other news, insider Fred M. Powell purchased 130,000 shares of the company’s stock in a transaction that occurred on Friday, June 9th. The shares were bought at an average cost of $2.79 per share, with a total value of $362,700.00. Following the completion of the transaction, the insider now directly owns 331,434 shares of the company’s stock, valued at $924,700.86. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 11.60% of the stock is owned by company insiders.
Antares Pharma Company Profile
Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges.
Receive News & Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
